Symons Capital Management Inc. Has $4.83 Million Position in Bristol-Myers Squibb Co (NYSE:BMY)

Symons Capital Management Inc. reduced its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 9.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 95,188 shares of the biopharmaceutical company’s stock after selling 9,524 shares during the period. Bristol-Myers Squibb makes up about 2.2% of Symons Capital Management Inc.’s portfolio, making the stock its 22nd biggest holding. Symons Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $4,827,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in BMY. Nuveen Asset Management LLC lifted its holdings in Bristol-Myers Squibb by 14,860.1% during the 2nd quarter. Nuveen Asset Management LLC now owns 9,395,120 shares of the biopharmaceutical company’s stock worth $426,069,000 after purchasing an additional 9,332,319 shares during the last quarter. Baupost Group LLC MA lifted its holdings in Bristol-Myers Squibb by 225.0% during the 2nd quarter. Baupost Group LLC MA now owns 13,000,000 shares of the biopharmaceutical company’s stock worth $589,550,000 after purchasing an additional 9,000,000 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Bristol-Myers Squibb by 67.6% during the 2nd quarter. Renaissance Technologies LLC now owns 20,698,607 shares of the biopharmaceutical company’s stock worth $938,682,000 after purchasing an additional 8,347,432 shares during the last quarter. BlackRock Inc. lifted its holdings in Bristol-Myers Squibb by 6.7% during the 2nd quarter. BlackRock Inc. now owns 114,798,394 shares of the biopharmaceutical company’s stock worth $5,206,108,000 after purchasing an additional 7,178,698 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in Bristol-Myers Squibb by 75.7% during the 2nd quarter. Janus Henderson Group PLC now owns 16,156,559 shares of the biopharmaceutical company’s stock worth $732,691,000 after purchasing an additional 6,960,047 shares during the last quarter. 80.40% of the stock is owned by institutional investors and hedge funds.

In other news, SVP John E. Elicker sold 15,000 shares of Bristol-Myers Squibb stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total value of $849,900.00. Following the transaction, the senior vice president now owns 74,471 shares in the company, valued at approximately $4,219,526.86. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Louis S. Schmukler sold 25,000 shares of Bristol-Myers Squibb stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $56.56, for a total value of $1,414,000.00. Following the completion of the transaction, the insider now owns 31,963 shares in the company, valued at approximately $1,807,827.28. The disclosure for this sale can be found here. Company insiders own 0.13% of the company’s stock.

NYSE BMY traded up $0.44 during midday trading on Friday, hitting $58.02. The company had a trading volume of 11,418,626 shares, compared to its average volume of 12,766,524. The company has a market capitalization of $91.88 billion, a PE ratio of 14.58, a P/E/G ratio of 1.31 and a beta of 0.71. The company has a current ratio of 3.83, a quick ratio of 3.72 and a debt-to-equity ratio of 1.37. The firm has a 50-day moving average price of $52.90 and a 200-day moving average price of $48.19. Bristol-Myers Squibb Co has a twelve month low of $42.48 and a twelve month high of $58.46.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The firm had revenue of $6.01 billion during the quarter, compared to analysts’ expectations of $5.89 billion. During the same period in the previous year, the firm earned $1.09 EPS. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. On average, equities analysts anticipate that Bristol-Myers Squibb Co will post 4.33 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were paid a $0.41 dividend. The ex-dividend date was Thursday, October 3rd. This represents a $1.64 annualized dividend and a dividend yield of 2.83%. Bristol-Myers Squibb’s payout ratio is 41.21%.

Several analysts recently weighed in on BMY shares. TheStreet raised Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a report on Wednesday, September 18th. UBS Group lifted their price target on Bristol-Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a report on Wednesday, October 23rd. Atlantic Securities raised Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price objective for the company in a report on Wednesday, August 14th. ValuEngine cut Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a report on Friday, October 25th. Finally, Bank of America assumed coverage on Bristol-Myers Squibb in a report on Wednesday, October 16th. They issued a “buy” rating and a $60.00 price objective for the company. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $56.64.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Further Reading: What are the advantages of the Stochastic Momentum Index?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Leave a Reply

Your email address will not be published. Required fields are marked *

*